Results: 4

2.
Figure 4

Figure 4. Aberrant SHMs affect promoter activity.. From: Genome-Wide Detection of Genes Targeted by Non-Ig Somatic Hypermutation in Lymphoma.

The effects of selected SHMs on BCL6 or BACH2 promoter activities were tested by dual luciferase assay in OCI-Ly1. Reporter activity of promoter bearing individual SHM was normalized to reporter activity of the wild-type promoter. Error bars indicate standard errors of three independent experiments.

Yanwen Jiang, et al. PLoS One. 2012;7(7):e40332.
3.
Figure 2

Figure 2. Novel promoter SNVs target important B cell genes in DLBCL.. From: Genome-Wide Detection of Genes Targeted by Non-Ig Somatic Hypermutation in Lymphoma.

iPAGE analysis using Gene Ontology database (#) or a lymphoid specific gene set database (*) showing strong enrichment of genes that are important for germinal center B cells and DLBCLs contain novel promoter SNVs in OCI-Ly1 and OCI-Ly8 cells.

Yanwen Jiang, et al. PLoS One. 2012;7(7):e40332.
4.
Figure 3

Figure 3. Detection of SHM.. From: Genome-Wide Detection of Genes Targeted by Non-Ig Somatic Hypermutation in Lymphoma.

(A). A snapshot of UCSC genome browser showing H3K4me3 ChIP-seq reads density at BACH2 promoter. The top three tracks represent SHMs, novel SNVs, and known SNVs (SNP132) detected in OCI-Ly1 by applying SHMseeqer to OCI-Ly1 H3K4me3 ChIP-seq short reads. (B). OCI-Ly1 H3K4me3 ChIP-seq short reads spanning chr6 position 91062534 (BACH2 intron 1) where a SHM was detected (shaded). (C). Sanger sequencing trace showing detection of both G (wild-type) and A (mutation) at chr6 position 91062534 in OCI-Ly1. (D). Overall validation rates of selected SNVs/SHMs within BACH2, BCL2, BCL6, BTG2, and MYO1E loci. N indicates number of SNVs/SHMs validated by Sanger sequencing in each locus.

Yanwen Jiang, et al. PLoS One. 2012;7(7):e40332.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk